Indiana University Simon Cancer Center re-designated as NCI cancer center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE INDIANA UNIVERSITY Melvin and Bren Simon Cancer Center was recognized by NCI as a designated cancer center, and had their support grant increased by 20 percent, following an in-depth peer review.

NCI rated the cancer center’s research activities as “excellent,” and awarded it a five-year, $7.8 million support grant. The NCI designation places the IU Simon Cancer Center in a group of 68 cancer centers. It is the only NCI-designated cancer center in Indiana that provides patient care. The center first received the NCI designation in 1999, seven years after its founding.

“We are especially honored to be renewed with this very prized designation again,” said Patrick Loehrer, director of the IU Simon Cancer Center. “To receive a funding increase in the current funding climate is icing on the cake.”

Reviewers, composed of NCI officials and others from NCI-designated cancer centers, evaluated the cancer center’s five research programs and visited in February 2014. Members of those research programs are on the Indiana University-Purdue University Indianapolis, IU Bloomington, IU South Bend and Notre Dame campuses.

YOU MAY BE INTERESTED IN

Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login